BACKGROUND: Clinical benefits of presurgical axitinib therapy for renal cell carcinoma (RCC) extending into the inferior vena cava (IVC) remain unclear. We aimed to investigate surgical benefits and pathological antitumor effects of presurgical axitinib therapy for RCC with IVC thrombus. METHODS: Of 56 consecutive RCC patients with IVC thrombus between January 1994 and December 2016, 41 patients who underwent radical nephrectomy (RN) were categorized as upfront RN (Upfront group) or presurgical axitinib followed by RN (Presurgical group). We retrospectively evaluated safety, radiologic tumor responses, and Ki-67 proliferation index before and after axitinib administration in the Presurgical group. Surgical outcomes, postoperative complications, and fibrosis within the IVC thrombus were compared between the Upfront and Presurgical groups. RESULTS: The number of patients in the Upfront and Presurgical groups was 31 and 10, respectively. Major presurgical axitinib-related adverse events were grade 2 or 3 hypertension (50%). The median radiological tumor response in the renal tumor, IVC thrombus length, and IVC thrombus volume were -19%, -21 mm, and -54%, respectively. The fibrosis within the IVC thrombus was significantly higher in the Presurgical group (10%) than in the Upfront group (3.4%). The Ki-67 proliferation index was significantly decreased in RN specimens (7.3%) versus needle biopsy specimens (23%) in the Presurgical group. Blood loss and operative duration were significantly lower and shorter, respectively, in the Presurgical group than in the Upfront group. CONCLUSIONS: Presurgical axitinib therapy enhanced tumor reduction accompanied by fibrosis and may contribute to surgical risk reduction for selected patients.
BACKGROUND: Clinical benefits of presurgical axitinib therapy for renal cell carcinoma (RCC) extending into the inferior vena cava (IVC) remain unclear. We aimed to investigate surgical benefits and pathological antitumor effects of presurgical axitinib therapy for RCC with IVC thrombus. METHODS: Of 56 consecutive RCCpatients with IVC thrombus between January 1994 and December 2016, 41 patients who underwent radical nephrectomy (RN) were categorized as upfront RN (Upfront group) or presurgical axitinib followed by RN (Presurgical group). We retrospectively evaluated safety, radiologic tumor responses, and Ki-67 proliferation index before and after axitinib administration in the Presurgical group. Surgical outcomes, postoperative complications, and fibrosis within the IVC thrombus were compared between the Upfront and Presurgical groups. RESULTS: The number of patients in the Upfront and Presurgical groups was 31 and 10, respectively. Major presurgical axitinib-related adverse events were grade 2 or 3 hypertension (50%). The median radiological tumor response in the renal tumor, IVC thrombus length, and IVC thrombus volume were -19%, -21 mm, and -54%, respectively. The fibrosis within the IVC thrombus was significantly higher in the Presurgical group (10%) than in the Upfront group (3.4%). The Ki-67 proliferation index was significantly decreased in RN specimens (7.3%) versus needle biopsy specimens (23%) in the Presurgical group. Blood loss and operative duration were significantly lower and shorter, respectively, in the Presurgical group than in the Upfront group. CONCLUSIONS: Presurgical axitinib therapy enhanced tumor reduction accompanied by fibrosis and may contribute to surgical risk reduction for selected patients.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Andres J Schrader; Sandra Steffens; Thomas J Schnoeller; Mark Schrader; Markus A Kuczyk Journal: Int J Urol Date: 2012-05-28 Impact factor: 3.369
Authors: Jose A Karam; Catherine E Devine; Diana L Urbauer; Marisa Lozano; Tapati Maity; Kamran Ahrar; Pheroze Tamboli; Nizar M Tannir; Christopher G Wood Journal: Eur Urol Date: 2014-02-07 Impact factor: 20.096
Authors: Brian I Rini; Jorge Garcia; Paul Elson; Laura Wood; Shetal Shah; Andrew Stephenson; Mohammed Salem; Michael Gong; Amr Fergany; John Rabets; Jihad Kaouk; Venkatesh Krishnamurthi; Eric Klein; Robert Dreicer; Steven Campbell Journal: J Urol Date: 2012-03-14 Impact factor: 7.450
Authors: Brian I Rini; Elizabeth R Plimack; Toshio Takagi; Paul Elson; Laura S Wood; Robert Dreicer; Timothy Gilligan; Jorge Garcia; Zhiling Zhang; Jihad Kaouk; Venkatesh Krishnamurthi; Andrew J Stephenson; Amr Fergany; Eric A Klein; Robert G Uzzo; David Y T Chen; Steven C Campbell Journal: J Urol Date: 2015-03-23 Impact factor: 7.450
Authors: Nicholas G Cost; Scott E Delacroix; Joshua P Sleeper; Paul J Smith; Ramy F Youssef; Brian F Chapin; Jose A Karam; Stephen Culp; E Jason Abel; James Brugarolas; Ganesh V Raj; Arthur I Sagalowsky; Christopher G Wood; Vitaly Margulis Journal: Eur Urol Date: 2011-02-23 Impact factor: 20.096
Authors: Anil A Thomas; Brian I Rini; Brian R Lane; Jorge Garcia; Robert Dreicer; Eric A Klein; Andrew C Novick; Steven C Campbell Journal: J Urol Date: 2008-12-18 Impact factor: 7.450
Authors: Grant D Stewart; Sarah J Welsh; Stephan Ursprung; Ferdia A Gallagher; James O Jones; Jacqui Shields; Christopher G Smith; Thomas J Mitchell; Anne Y Warren; Axel Bex; Ekaterini Boleti; Jade Carruthers; Tim Eisen; Kate Fife; Abdel Hamid; Alexander Laird; Steve Leung; Jahangeer Malik; Iosif A Mendichovszky; Faiz Mumtaz; Grenville Oades; Andrew N Priest; Antony C P Riddick; Balaji Venugopal; Michelle Welsh; Kathleen Riddle; Lisa E M Hopcroft; Robert J Jones Journal: Br J Cancer Date: 2022-06-23 Impact factor: 9.075